Advertisement
Humacyte Inc. (HUMA)
Humacyte Statistics
Share Statistics
Humacyte has 155.12M shares outstanding. The number of shares has increased by 29.04% in one year.
| Shares Outstanding | 155.12M |
| Shares Change (YoY) | 29.04% |
| Shares Change (QoQ) | 19.43% |
| Owned by Institutions (%) | 35.25% |
| Shares Floating | 272.24M |
| Failed to Deliver (FTD) Shares | 111.81K |
| FTD / Avg. Volume | 3.12% |
Short Selling Information
The latest short interest is 26.09M, so 16.98% of the outstanding shares have been sold short.
| Short Interest | 26.09M |
| Short % of Shares Out | 16.98% |
| Short % of Float | 20.89% |
| Short Ratio (days to cover) | 4.58 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -7.94. Humacyte's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -7.94 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | -11.36 |
| P/FCF Ratio | -6 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Humacyte.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.4, with a Debt / Equity ratio of -0.31.
| Current Ratio | 2.4 |
| Quick Ratio | 2.4 |
| Debt / Equity | -0.31 |
| Debt / EBITDA | -0.14 |
| Debt / FCF | -0.17 |
| Interest Coverage | 12.33 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $0 |
| Employee Count | 218 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -64.3% in the last 52 weeks. The beta is 1.62, so Humacyte's price volatility has been higher than the market average.
| Beta | 1.62 |
| 52-Week Price Change | -64.3% |
| 50-Day Moving Average | 2.46 |
| 200-Day Moving Average | 4.76 |
| Relative Strength Index (RSI) | 36.73 |
| Average Volume (20 Days) | 3.58M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -114.4M |
| Net Income | 0 |
| EBITDA | -114.4M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.26 |
Balance Sheet
The company has 44.94M in cash and 16.54M in debt, giving a net cash position of 28.4M.
| Cash & Cash Equivalents | 44.94M |
| Total Debt | 16.54M |
| Net Cash | 28.4M |
| Retained Earnings | -686.01M |
| Total Assets | 137.87M |
| Working Capital | 27.91M |
Cash Flow
In the last 12 months, operating cash flow was -98.12M and capital expenditures -1.57M, giving a free cash flow of -99.69M.
| Operating Cash Flow | -98.12M |
| Capital Expenditures | -1.57M |
| Free Cash Flow | -99.69M |
| FCF Per Share | -0.84 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HUMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for HUMA is $14, which is 858.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $14 |
| Price Target Difference | 858.9% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -9.17 |
| Piotroski F-Score | 1 |